News Release Detail
Mylan Receives Approval for Mercaptopurine Tablets USP, 50 mg
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.
This press release includes statements that constitute "forward-looking statements," including with regard to the availability of Mercaptopurine. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the possible negative effects of any interruption of manufacture of the product; uncertainties regarding market acceptance and demand for the product; dependence on third-party suppliers and distributors for raw materials; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
SOURCE Mylan Laboratories Inc.
07/07/2005
CONTACT: Patrick Fitzgerald, Public Relations, or Kris King, Investor
Relations of Mylan Laboratories Inc., +1-724-514-1800
Web site: http://www.mylan.com